Delving into the Latest Updates on Yun He Yi Yao （ Tian Jin ） You Xian Gong Si with Synapse

Overview

Tags

Urogenital Diseases

Neoplasms

Chemical drugs

Therapeutic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Chemical drugs	2
Therapeutic radiopharmaceuticals	1

Top 5 Target	Count

PSMA(Prostate-specific membrane antigen)	2

[Translation] A multicenter, open-label, non-randomized phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

I期：评价INR102在PSMA阳性mCRPC受试者中的安全性和耐受性；确定INR102单次给药的剂量限制性毒性（DLT）（如有）、最大耐受剂量（MTD）（如有），以及Ⅱa期研究推荐剂量（RP2D）。Ⅱa期：评价INR102在PSMA阳性mCRPC受试者中的初步抗肿瘤活性。

[Translation]

Phase I: Evaluate the safety and tolerability of INR102 in PSMA-positive mCRPC subjects; determine the dose-limiting toxicity (DLT) (if any), maximum tolerated dose (MTD) (if any) of a single dose of INR102, and the recommended dose (RP2D) for Phase IIa studies. Phase IIa: Evaluate the preliminary anti-tumor activity of INR102 in PSMA-positive mCRPC subjects.

Start Date-

Sponsor / Collaborator

Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

CTR20241842

/ Active, not recruitingPhase 1/2

INR101 注射液 PET/CT 在健康男性受试者和可疑前列腺癌患者成像的多中心、开放Ⅰ/Ⅱa 期临床试验

[Translation] A multicenter, open-label, phase I/IIa clinical trial of INR101 injection PET/CT imaging in healthy male subjects and patients with suspected prostate cancer

Ⅰ期：评价 INR101 注射液在中国健康男性受试者体内的生物分布、辐射剂量学及药代动力学（PK）特征。评价 INR101 注射液在中国健康男性受试者中的安全性。 Ⅱa期：在前列腺区域水平，以前列腺穿刺病理结果为真实性标准，根据 INR101 注射液 PET/CT 在不同剂量和成像时间的诊断效能，确定最佳成像条件。

[Translation]

Phase I: Evaluate the biodistribution, radiation dosimetry and pharmacokinetic (PK) characteristics of INR101 injection in healthy Chinese male subjects. Evaluate the safety of INR101 injection in healthy Chinese male subjects. Phase IIa: At the prostate regional level, using the prostate puncture pathology results as the authenticity standard, determine the optimal imaging conditions based on the diagnostic efficacy of INR101 injection PET/CT at different doses and imaging times.

Start Date22 May 2024

Sponsor / Collaborator

Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

100 Clinical Results associated with Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

Login to view more data

0 Patents (Medical) associated with Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

Login to view more data

100 Deals associated with Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

Login to view more data

100 Translational Medicine associated with Yun He Yi Yao （ Tian Jin ） You Xian Gong Si

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Phase 3 Clinical

Login to view more data